Holen Sie sich die Stockscreener-App
1.35
2.27%
0.03
Handel nachbörslich:
1.34
-0.01
-0.74%
Schlusskurs vom Vortag:
$1.32
Offen:
$1.32
24-Stunden-Volumen:
1.98M
Relative Volume:
0.65
Marktkapitalisierung:
$1.07B
Einnahmen:
$711.41M
Nettoeinkommen (Verlust:
$-133.73M
KGV:
-7.1053
EPS:
-0.19
Netto-Cashflow:
$-199.99M
1W Leistung:
+6.30%
1M Leistung:
+0.00%
6M Leistung:
-18.67%
1J Leistung:
-11.18%
1-Tages-Spanne:
$1.32
$1.37
1-Wochen-Bereich:
$1.22
$1.37
52-Wochen-Spanne:
$1.11
$2.035
Opko Health Inc Stock (OPK) Company Profile
Firmenname
Opko Health Inc
Sektor
Branche
Telefon
305-575-4181
Adresse
4400 BISCAYNE BLVD., MIAMI, FL
Vergleichen Sie OPK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.35 | 1.03B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 180.28B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 147.31B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.92 | 52.18B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 33.33B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 31.60B | 15.50B | 1.33B | 2.16B | 7.34 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-25 | Eingeleitet | JP Morgan | Neutral |
| 2023-06-29 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-24 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-11-25 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-03-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-06-21 | Bestätigt | Standpoint Research | Buy |
| 2016-06-03 | Eingeleitet | Standpoint Research | Buy |
| 2016-03-31 | Bestätigt | Barrington Research | Outperform |
| 2015-10-16 | Eingeleitet | JP Morgan | Overweight |
| 2015-09-11 | Herabstufung | Jefferies | Buy → Hold |
| 2015-03-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2014-05-12 | Bestätigt | Oppenheimer | Outperform |
| 2014-03-14 | Eingeleitet | Oppenheimer | Outperform |
| 2013-11-13 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-05-30 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-10-22 | Eingeleitet | Barrington Research | Outperform |
| 2011-12-01 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-07-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Opko Health Inc Aktie (OPK) Neueste Nachrichten
Phillip Md Et Al Frost Purchases 675,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock - MarketBeat
OPKO Health (NASDAQ:OPK) Shares Gap Up Following Insider Buying Activity - MarketBeat
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) - MSN
Y.D. More Investments Ltd Has $2.97 Million Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Is OPKO Health Inc. affected by consumer sentimentBreakout Stocks with Huge Upside - newsyoung.net
Phillip Frost Spends US$891k On OPKO Health Stock - simplywall.st
Phillip Frost Buys Handful Of Shares In OPKO Health - Yahoo Finance
OPKO Health Q3 EPS Estimate Reduced by Barrington Research - MarketBeat
Phillip Frost's Significant Investment in Opko Health: A Bold Move - AInvest
Opko Health’s CEO Makes a Bold Move with Massive Stock Purchase! - TipRanks
Quote - OPKO Health, Inc.
Entera Bio Beats Q2 EPS Estimates - The Motley Fool
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Opko Health (OPK) Q2 Revenue Falls 14% - AOL.com
OPKO Health (OPK) Q2 2025 Earnings Call Transcript - AOL.com
OPKO Health, Inc. (NASDAQ:OPK) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
OPKO Health (NASDAQ:OPK) Sets New 52-Week Low on Disappointing Earnings - MarketBeat
Acromegaly Pipeline 2025: Key Companies, MOA, ROA, and Clinical - openPR.com
Opko Health (OPK) Reports Fiscal Q2 2025 Results - Insider Monkey
Optimistic Growth Prospects for OPKO Health: Buy Rating with 89% Upside Potential - TipRanks
Can OPKO Health Inc. Outperform Peers After Recent PullbackAccurate Technical Trend Reversal Picks Detected - metal.it
What analysts say about OPKO Health Inc. stockFree Stock Index Interpretation - Jammu Links News
What is the dividend policy of OPKO Health Inc. stockInvest confidently with data-backed picks - Jammu Links News
OPKO Health Inc. Stock Analysis and ForecastUnrivaled growth potential - Jammu Links News
What drives OPKO Health Inc. stock priceBuild wealth steadily with smart stock selection - Jammu Links News
What makes OPKO Health Inc. stock price move sharplyOutstanding investment returns - Jammu Links News
What is OPKO Health Inc. company’s growth strategyMaximize gains with professional stock picks - Jammu Links News
What are the latest earnings results for OPKO Health Inc.Achieve breakthrough performance with smart picks - Jammu Links News
Is OPKO Health Inc. a growth stock or a value stockUnlock exclusive stock market forecasts - Jammu Links News
Why is OPKO Health Inc. stock attracting strong analyst attentionSuperior stock growth - Jammu Links News
How many analysts rate OPKO Health Inc. as a “Buy”Phenomenal wealth increase - Jammu Links News
Is it the right time to buy OPKO Health Inc. stockBuild a diversified portfolio for risk mitigation - Jammu Links News
OPKO Health (OPK.O) Plummets 7% Amid Oversold RSI and Weak Sector Sentiment - AInvest
What is the risk reward ratio of investing in OPKO Health Inc. stockGet exclusive market insights for better trading - Jammu Links News
What institutional investors are buying OPKO Health Inc. stockMaximize portfolio value with smart investment plans - Jammu Links News
What are OPKO Health Inc. company’s key revenue driversGet alerts on top growth stocks daily - Jammu Links News
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands - MSN
OPKO Health Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
GSA Capital Partners LLP Boosts Stock Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health (OPK.O) Plunges 9.77%: What's Behind the Sharp Intraday Drop? - AInvest
OPKO Health's Strategic Asset Sale to Labcorp: A Financial Boost and Strong Analyst Expectations - AInvest
OPKO Health outlines $640M–$660M 2025 revenue target as BioReference sale and pipeline advances drive profitability push - MSN
OPKO Health (OPK.O) Dives 9.28%—What’s Behind the Sharp Intraday Drop? - AInvest
Finanzdaten der Opko Health Inc-Aktie (OPK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Opko Health Inc-Aktie (OPK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 10 '25 |
Buy |
1.36 |
125,000 |
169,712 |
214,001,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 08 '25 |
Buy |
1.48 |
125,000 |
184,650 |
213,876,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 01 '25 |
Buy |
1.65 |
100,000 |
164,850 |
213,751,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 28 '25 |
Buy |
1.70 |
150,000 |
254,385 |
213,651,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 17 '25 |
Buy |
1.74 |
200,000 |
347,820 |
213,501,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '25 |
Buy |
1.71 |
67,434 |
115,312 |
213,301,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 28 '25 |
Buy |
1.47 |
47,537 |
70,060 |
213,234,014 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 17 '25 |
Buy |
1.47 |
150,000 |
220,425 |
213,186,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
3.96%
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):